Development of sandwich ELISAs that can distinguish different types of coxsackievirus A16 viral particles

Applied Microbiology and Biotechnology

Volumn 100, Issue 6, 2016, Pages 2809-2815

  Ye, Xiangzhong ^a   Yang, Lisheng ^b   Jia, Jizong ^a   Han, Jinle ^a   Li, Shuxuan ^b   Liu, Yajing ^b   Xu, Longfa ^b   Zhao, Huan ^b   Chen, Yixin ^b   Li, Yimin ^a   Cheng, Tong ^b   Xia, Ningshao ^b  

^a Beijing Wantai Biological Pharmacy Enterprise ^*  (China)

^b XIAMEN UNIVERSITY   (China)

Author keywords

Antibody; Coxsackievirus A16; Enzyme linked immunoassay; Hand, foot, and mouth disease; Particle; Vaccine

Indexed keywords

ANTIBODIES; BINS; ENZYMES; MONOCLONAL ANTIBODIES; PARTICLES (PARTICULATE MATTER); SURFACE PLASMON RESONANCE; THERMODYNAMIC STABILITY;

CAUSATIVE AGENTS; CLINICAL TRIAL; COXSACKIEVIRUS A16; ENZYME LINKED IMMUNOASSAYS; IMMUNOGENICITY; MONOCLONAL ANTIBODIES (MABS); VIRAL PARTICLES;

VACCINES;

MONOCLONAL ANTIBODY; ORAL POLIOMYELITIS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANTIBODY; DISEASE INCIDENCE; DRUG DEVELOPMENT; IMMUNOASSAY; IMMUNOCOMPETENCE; VACCINE; VIRAL DISEASE; VIRUS PARTICLE;

AMINO ACID SEQUENCE; ARTICLE; COXSACKIEVIRUS A16; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW RATE; IMMUNOGENICITY; NONHUMAN; SEDIMENTATION RATE; THERMOSTABILITY; VIRUS CAPSID; VIRUS CHARACTERIZATION; VIRUS PARTICLE; CLASSIFICATION; ENTEROVIRUS; IMMUNOLOGY; PROCEDURES; VIRION; VIROLOGY;

COXSACKIEVIRUS; MIRIDAE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ENTEROVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; VIRION; VIROLOGY;

EID: 84954323888     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-016-7296-z     Document Type: Article

References (26)

1. Bruu AL (2003) Enteroviruses: polioviruses, coxsackieviruses, echoviruses and newer enteroviruses. A Practical Guide to Clinical Virology, Second Edition, pp. 44–45
2. Bubeck D, Filman DJ, Cheng N, Steven AC, Hogle JM, Belnap DM (2005) The structure of the poliovirus 135S cell entry intermediate at 10-angstrom resolution reveals the location of an externalized polypeptide that binds to membranes. J Virol 79(12):7745–7755. doi:10.1128/JVI.79.12.7745-7755.2005
3. Butan C, Filman DJ, Hogle JM (2014) Cryo-electron microscopy reconstruction shows poliovirus 135S particles poised for membrane interaction and RNA release. J Virol 88(3):1758–1770. doi:10.1128/JVI.01949-13
4. Chen Y, Li C, He D, Cheng T, Ge S, Shih JW, Zhao Q, Chen PJ, Zhang J, Xia N (2012) Antigenic analysis of divergent genotypes human enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: current genotyping of EV71 does not reflect their antigenicity. Vaccine. doi:10.1016/j.vaccine. 2012.10.032
5. Chong P, Guo MS, Lin FH, Hsiao KN, Weng SY, Chou AH, Wang JR, Hsieh SY, Su IJ, Liu CC (2012) Immunological and biochemical characterization of Coxsackie virus A16 viral particles. PLoS One 7(11):e49973. doi:10.1371/journal.pone.0049973
6. Ferguson M, Minor PD, Magrath DI, Qui YH, Spitz M, Schild GC (1984) Neutralization epitopes on poliovirus type 3 particles: an analysis using monoclonal antibodies. J Gen Virol 65(Pt 1) Jan:197–201. doi:10.1099/0022-1317-65-1-197
7. Ferguson M, Wood DJ, Minor PD (1993) Antigenic structure of poliovirus in inactivated vaccines. J Gen Virol 74(Pt 4):685–690. doi:10.1099/0022-1317-74-4-685
8. Fricks CE, Hogle JM (1990) Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding. J Virol 64(5):1934–1945
9. Galazka A, Milstien J, Zaffran M (1998) Thermostability of vaccines. World Health Organization, Global Programme for Vaccines and Immunization
10. Hou W, Yang L, He D, Zheng J, Xu L, Liu J, Liu Y, Zhao H, Ye X, Cheng T, Xia N (2015) Development of a coxsackievirus A16 neutralization test based on the enzyme-linked immunospot assay. J Virol Methods 215-216(0):56–60. doi:10.1016/j.jviromet. 2015.02.010
11. Li L, He Y, Yang H, Zhu J, Xu X, Dong J, Zhu Y, Jin Q (2005) Genetic characteristics of human enterovirus 71 and coxsackievirus A16 circulating from 1999 to 2004 in Shenzhen, People’s Republic of China. J Clin Microbiol 43(8):3835–3839. doi:10.1128/JCM.43.8.3835-3839.2005
12. Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, Jiang L, Dong C, Che Y, Huang T, Jiang Z, Xie Z, Wang L, Liao Y, Liang Y, Nong Y, Liu J, Zhao H, Na R, Guo L, Pu J, Yang E, Sun L, Cui P, Shi H, Wang J, Li Q (2014) An inactivated enterovirus 71 vaccine in healthy children. New Engl J Med 370(9):829–837. doi:10.1056/NEJMoa1303224
13. Li S, Tang X, Seetharaman J, Yang C, Gu Y, Zhang J, Du H, Shih JW, Hew CL, Sivaraman J, Xia N (2009) Dimerization of hepatitis E virus capsid protein E2s domain is essential for virus-host interaction. PLoS Pathog 5(8):e1000537. doi:10.1371/journal.ppat.1000537
14. Liu Q, Tong X, Huang Z (2015) Towards broadly protective polyvalent vaccines against hand, foot and mouth disease. Microbes Infect 17(2):155–162. doi:10.1016/j.micinf. 2014.11.004
15. Nakane PK, Kawaoi A (1974) Peroxidase-labeled antibody. A new method of conjugation. J Histochem Cytochem 22(12):1084–1091
16. Ren J, Wang X, Hu Z, Gao Q, Sun Y, Li X, Porta C, Walter TS, Gilbert RJ, Zhao Y, Axford D, Williams M, McAuley K, Rowlands DJ, Yin W, Wang J, Stuart DI, Rao Z, Fry EE (2013) Picornavirus uncoating intermediate captured in atomic detail. Nat Commun 4:1929. doi:10.1038/ncomms2889
17. Ren J, Wang X, Zhu L, Hu Z, Gao Q, Yang P, Li X, Wang J, Shen X, Fry EE, Rao Z, Stuart DI (2015) Structures of coxsackievirus A16 capsids with native antigenicity: implications for particle expansion, receptor binding, and immunogenicity. J Virol 89(20):10500–10511. doi:10.1128/JVI.01102-15
18. Schuck P, Rossmanith P (2000) Determination of the sedimentation coefficient distribution by least-squares boundary modeling. Biopolymers 54(5):328–341. doi:10.1002/1097-0282(20001015)54:5<328::AID-BIP40>3.0.CO;2-P
19. Shingler KL, Yoder JL, Carnegie MS, Ashley RE, Makhov AM, Conway JF, Hafenstein S (2013) The enterovirus 71 A-particle forms a gateway to allow genome release: a cryoEM study of picornavirus uncoating. PLoS Pathog 9(3):e1003240. doi:10.1371/journal.ppat.1003240
20. Singer C, Knauert F, Bushar G, Klutch M, Lundquist R, Quinnan GV (1989) Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent-assay using animal sera and monoclonal-antibodies. J Biol Stand 17(2):137–150. doi:10.1016/0092-1157(89)90004-8
21. Somasundaram B, Lua LH (2015) Development of picornavirus-like particle vaccines. Pharmaceutical Bioprocessing 3(1):45–59
22. Wallis C, Menick JL (1962) Cationic stabilization—a new property of enteroviruses. Virology 16:504–506
23. Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C, Walter TS, Evans G, Axford D, Owen R, Rowlands DJ, Wang J, Stuart DI, Fry EE, Rao Z (2012) A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 19(4):424–429. doi:10.1038/nsmb.2255
24. Yang E, Cheng C, Zhang Y, Wang J, Che Y, Pu J, Dong C, Liu L, He Z, Lu S, Zhao Y, Jiang L, Liao Y, Shao C, Li Q (2014) Comparative study of the immunogenicity in mice and monkeys of an inactivated CA16 vaccine made from a human diploid cell line. Hum Vacc Immunother 10(5):1266–1273. doi:10.4161/hv.28083
25. Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, Hu Y, Ji T, Song L, Liang Q, Zhang B, Gao Q, Li J, Wang S, Hu Y, Gu S, Zhang J, Yao G, Gu J, Wang X, Zhou Y, Chen C, Zhang M, Cao M, Wang J, Wang H, Wang N (2014) Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. New Engl J Med 370(9):818–828. doi:10.1056/NEJMoa1304923
26. Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, Hu YM, Wu X, Liu P, Zhu LY, Gao F, Jin H, Chen YJ, Dong YY, Liang YC, Shi NM, Ge HM, Liu L, Chen SG, Ai X, Zhang ZY, Ji YG, Luo FJ, Chen XQ, Zhang Y, Zhu LW, Liang ZL, Shen XL (2013) Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 381(9882):2024–2032. doi:10.1016/S0140-6736(13)61049-1